These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25870375)

  • 21. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
    Flaherty KT; Schiller J; Schuchter LM; Liu G; Tuveson DA; Redlinger M; Lathia C; Xia C; Petrenciuc O; Hingorani SR; Jacobetz MA; Van Belle PA; Elder D; Brose MS; Weber BL; Albertini MR; O'Dwyer PJ
    Clin Cancer Res; 2008 Aug; 14(15):4836-42. PubMed ID: 18676756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary pulmonary hepatoid adenocarcinoma: A case report and review of the literature.
    Yang K; Jiang H; Li Q
    Medicine (Baltimore); 2019 Apr; 98(14):e15053. PubMed ID: 30946350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
    Maida M; Macaluso FS; Valenza F; Virdone R
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
    Tabernero J; Garcia-Carbonero R; Cassidy J; Sobrero A; Van Cutsem E; Köhne CH; Tejpar S; Gladkov O; Davidenko I; Salazar R; Vladimirova L; Cheporov S; Burdaeva O; Rivera F; Samuel L; Bulavina I; Potter V; Chang YL; Lokker NA; O'Dwyer PJ
    Clin Cancer Res; 2013 May; 19(9):2541-50. PubMed ID: 23532888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
    Spigel DR; Rubin MS; Gian VG; Shipley DL; Burris HA; Kosloff RA; Shih KC; Quinn R; Greco FA; Hainsworth JD
    Lung Cancer; 2017 Nov; 113():79-84. PubMed ID: 29110854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
    Sereno M; Moreno V; Moreno Rubio J; Gómez-Raposo C; García Sánchez S; Hernández Jusdado R; Falagan S; Zambrana Tébar F; Casado Sáenz E
    Anticancer Drugs; 2015 Oct; 26(9):1004-7. PubMed ID: 26237499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
    Novello S; Vavalà T; Levra MG; Solitro F; Pelosi E; Veltri A; Scagliotti GV
    Clin Lung Cancer; 2013 May; 14(3):230-7. PubMed ID: 23276821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatoid adenocarcinoma of the stomach: case report and short notes on immunohistochemical markers.
    Augustin G; Jelincic Z; Tentor D; Majerovic M; Matosevic P
    Acta Gastroenterol Belg; 2009; 72(2):253-6. PubMed ID: 19637784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hepatoid Adenocarcinoma of the Lung with High Serum AFP and CEA Values;Report of a Case].
    Nakashima K; Okagawa T
    Kyobu Geka; 2018 Jan; 71(1):76-79. PubMed ID: 29483483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy.
    Doherty MK; O'Connor E; Hannon D; O'Reilly A; Yen D; Redmond M; Grogan LM; Hennessy BT; Breathnach OS; Morris PG
    Ir J Med Sci; 2019 Feb; 188(1):69-74. PubMed ID: 29948461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
    Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with sorafenib in advanced thyroid cancer - a case report.
    Krajewska J; Olczyk T; Roskosz J; Paliczk-Cieślik E; Smietana AK; Kaczmarek-Borowska B; Jarząb B
    Endokrynol Pol; 2010; 61(5):492-6. PubMed ID: 21049464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
    Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
    J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nab-Paclitaxel with platinum chemotherapy as sixth-line therapy for a non-small cell lung cancer patient].
    Ishiura Y; Shiba Y; Terasaki Y; Hinoue Y; Ishida Y; Segawa M; Saitoh K; Hirokami N; Kasahara K; Fujimura M
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):493-5. PubMed ID: 25963700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatoid Adenocarcinoma of the Lung.
    Li M; Fan Y; Lu H
    Technol Cancer Res Treat; 2021; 20():15330338211057983. PubMed ID: 34816785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sorafenib-Sunitinib Sequence: The Jury Is Out.
    Albiges L; Escudier B
    Eur Urol; 2015 Nov; 68(5):848-9. PubMed ID: 26184972
    [No Abstract]   [Full Text] [Related]  

  • 39. Alpha-Fetoprotein-Producing Lung Hepatoid Adenocarcinoma with Brain Metastasis Treated with S-1.
    Muroyama Y; Tamiya H; Tanaka G; Tanaka W; Huang AC; Oldridge DA; Matsusaka K; Takazawa Y; Jo T; Ushiku T; Nagase T
    Case Rep Oncol; 2020; 13(3):1552-1559. PubMed ID: 33564297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
    Takeda H; Nishikawa H; Osaki Y; Tsuchiya K; Joko K; Ogawa C; Taniguchi H; Orito E; Uchida Y; Izumi N;
    Liver Int; 2015 May; 35(5):1581-9. PubMed ID: 24836552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.